Modification of Multidrug Resistance by Magnetic Exposure Indicated from the Point of View of Nuclear Medicine
Modification of Multidrug Resistance by Magnetic Exposure Indicated from the Point of View of Nuclear Medicine
批准号:
09670954
负责人:
NAKAMURA Kayoko
金额:
$1.98万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998
中文摘要
用~(99m)Tc-MIBI摄取法研究了磁场对肿瘤细胞化疗敏感性的影响,揭示了P-糖蛋白的功能。研究的细胞系是从患者建立的间变性甲状腺癌细胞系;人表皮样细胞KB-31;转导MDR基因KB-G2的KB-31;以及MRP-细胞系CA-500。短时(1小时)强磁场暴露后,部分肿瘤细胞(并非所有细胞)对~(99m)Tcm-MIBI的摄取减少。在弱磁场作用下,所有肿瘤细胞对~(99m)Tc-MIBI的摄取均增加。在抗P-糖蛋白抗体或抑制P-糖蛋白功能的维拉帕米存在时,这些作用不会改变。因此,可以得出结论,不同细胞的磁效应是不同的,并且这些效应不是P-糖蛋白所特有的。磁暴露可能是逆转肿瘤细胞多药耐药性的修饰之一。细胞对TC-99m-MIBI的摄取是评价多药耐药修饰的良好指标。
英文摘要
The effects of magnetic field on the chemosensitivity of tumor cells were investigated by using Tc-99m-MIBI uptake; which indicates the function of P-glycoprotein. The cells lines studies were anaplastic thyroid cancer cell lines established from patients; human epidermoid cell KB-31; KB-31 transfected with mdr gene KB-G2; and MRP-cell line CA-500. By the strong magnetic exposure for a short period (one hour) the Tc-99m-MIBI uptake in some tumor cells (not all cells) was reduced. Under weak magnetic field the Tc-99m-MIBI uptake was increased in all tumor cells studied. These effects were not altered in the presence of anti-P-glycoprotein antibody or verapamil that inhibits the function of P-glycoprotein. It can be, therefore, concluded that the magnetic effects were different from cell to cell, and that these effects were not specific for P-glycoprotein. Magnetic exposure may be one of modifications that reverse multidrug resistance of tumor cells. Tc-99m-MIBI uptake in cells is a good indicator to assess the multidrug resistance modification.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
K. Nakamura et al.: "Assessment of MDR-reversing agents by Tc-99m-MIBI"Anticancer Research. 18-6C. 4921 (1998)
K. Nakamura 等人:“通过 Tc-99m-MIBI 评估 MDR 逆转剂”抗癌研究。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nakamura K.et al,: "Assessment of MDR-reversing Agents by Tc-99m-MIBI" Anticancer Researcg. 18(6C). 4921 (1998)
Nakamura K.等人:“通过 Tc-99m-MIBI 评估 MDR 逆转剂”抗癌研究。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
K.Nakamura et al.: "In vivo evaluation of P-glycoprotein by T-125-labelled MRK-16 monoclonal antibody or Tc-99m-MIBI"European Journal of Nuclear Medicine. 24(8). 869 (1997)
K.Nakamura 等人:“通过 T-125 标记的 MRK-16 单克隆抗体或 Tc-99m-MIBI 对 P-糖蛋白进行体内评估”欧洲核医学杂志。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
K. Nakamura et al.: "In vivo evaluation of P-glycoprotein by I-125-labelled MRK-16 monoclonal antibody or Tc-99m-MIBI"European Journal of Nuclear Medicine. 24-8. 869 (1997)
K. Nakamura 等人:“通过 I-125 标记的 MRK-16 单克隆抗体或 Tc-99m-MIBI 对 P-糖蛋白进行体内评估”欧洲核医学杂志。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
K.Nakamura,et al: "In vivo evaluation of P-glycoprotein by I-125-labelled MRK-16 monoclonal antibody or Tc-99m-MIBI" European Journal of Nuclear Medicine. 24(8). 869- (1997)
K.Nakamura 等人:“通过 I-125 标记的 MRK-16 单克隆抗体或 Tc-99m-MIBI 对 P-糖蛋白进行体内评估”《欧洲核医学杂志》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 26 条
Optical and Nuclear Imaging of Tumor-related genes
-
批准号:19591434
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2007
-
负责人:NAKAMURA Kayoko
-
依托单位:
Gene Imaging for Studying Pharmacokinetics of Gene in Vivo at the Real Time
-
批准号:16591225
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2004
-
负责人:NAKAMURA Kayoko
-
依托单位:
In Vivo Diagnosis of Gene Localization and Expression by Nuclear Medicine Modality
-
批准号:13670965
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.56万
-
财政年份:2001
-
负责人:NAKAMURA Kayoko
-
依托单位:
Development of Nuclear Medicine Modality for Selecting Cancer Therapy and for Predicting Therapeutic Efficacy from Molecular Biological Points of View
-
批准号:11670912
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:1999
-
负责人:NAKAMURA Kayoko
-
依托单位:
Molecular Biological Approach towards Efficient Radioimmunotherapy
-
批准号:07671027
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.47万
-
财政年份:1995
-
负责人:NAKAMURA Kayoko
-
依托单位:
Pharmacokinetic Study of Targeting Tumors with Radio-and Drug-conjugated Monoclonal Antibody
-
批准号:05670785
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1993
-
负责人:NAKAMURA Kayoko
-
依托单位:
Biochemical and Immunological Characterization of Tumors by Immunoscintigraphy
-
批准号:63570496
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1988
-
负责人:NAKAMURA Kayoko
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于“Healthy-NAT-Tumor”三维度的食管鳞癌蛋白组学数据挖掘及其临床意义研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:刘伟
-
依托单位:
超级增强子驱动“CYTOR-FOSL1正反馈环路”促进口腔鳞癌Tumor budding转移的研究
-
批准号:82073265
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:王成
-
依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
-
批准号:82072862
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐云升
-
依托单位:
STAU1/TP63信号轴介导TINCR调控舌鳞癌tumor budding细胞干性维持
-
批准号:81802704
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:庄泽航
-
依托单位:
基于tumor cord-PBPK偶联模型的抗肿瘤药物药动学预测研究
-
批准号:81703454
-
项目类别:青年科学基金项目
-
资助金额:20.1万元
-
批准年份:2017
-
负责人:吴春暖
-
依托单位:
SUZ12 ceRNAs参与miR-320a调控舌鳞癌tumor budding侵袭转移的分子机制
-
批准号:81602380
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2016
-
负责人:谢楠
-
依托单位:
FOSL1 ceRNA网络调控舌鳞癌Tumor Budding细胞侵袭转移的分子机制
-
批准号:81572661
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2015
-
负责人:王成
-
依托单位: